A clinical-stage biotechnology company focused on developing targeted therapies for cancer and other serious diseases, with its lead programs aimed at inhibiting the GAS6/AXL signaling pathway linked to tumor growth and metastasis. The company’s pipeline has centered on batiraxcept, an investigation...
This page tracks all publicly disclosed congressional trades in Aravive, Inc. (ARAV), a company in the Healthcare sector. 1 member of Congress has disclosed trades in this stock, including 0 purchases and 1 sale. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-12-28 | BOB GIBBS | sell | $158+ |